

ASH Annual Meeting 2021 Stanford BMT-CT Oral and Poster Presentations

[Worsening Financial Toxicity Among Patients Receiving Chimeric Antigen Receptor t-Cell](#)

[\(CAR-T\) Therapy: A Mixed Methods Longitudinal Study](#); **Rachel Cusatis**^{1*}, Irena Tan, MD², Claire Piehowski, BS^{1*}, Idayat Akinola, MBBS, MPH^{1*}, Emma Crawford, BS^{3*}, Juliana Craig, BA^{4,5*}, Aline Thiengmany, BS^{6*}, Matthew J. Frank, MD, PhD⁷, David B. Miklos, MD, PhD⁷, Nirav N. Shah, MD⁸, Anita D'Souza, MD, MS^{9,10}, Jennifer M Knight, MD MS^{11*}, Lori Muffly, MD^{5,12}, Kathryn E Flynn, PhD^{13*} and Surbhi Sidana, MD^{5,12,14}

[Primary Analysis of ZUMA-7: A Phase 3 Randomized Trial of Axicabtagene Ciloleuce \(Axi-Cel\) Versus Standard-Of-Care Therapy in Patients With Relapsed/Refractory Large B-Cell](#)

[Lymphoma](#); **Frederick L. Locke, MD**¹, David B. Miklos, MD, PhD², Caron Jacobson, MD³, Miguel-Angel Perales, MD⁴, Marie José Kersten, MD, PhD⁵, Olalekan O. Oluwole, MBBS, MPH⁶, Armin Ghobadi, MD^{7*}, Aaron P. Rapoport, MD⁸, Joseph P. McGuirk, DO⁹, John M. Pagel, MD, PhD¹⁰, Javier Muñoz, MD, MS, MBA, FACP^{11*}, Umar Farooq, MD¹², Tom Van Meerten, MD, PhD^{13*}, Patrick M. Reagan, MD¹⁴, Anna Sureda¹⁵, Ian W. Flinn, MD, PhD¹⁶, Peter Vandenberghe, MD, PhD¹⁷, Kevin Song, MD, FRCPC¹⁸, Michael Dickinson, MBBS¹⁹, Monique C. Minnema, MD²⁰, Peter A. Riedell, MD²¹, Lori A. Leslie, MD^{22*}, Sridhar Chaganti, MD^{23*}, Yin Yang, MS, MD^{24*}, Simone Filosto, PhD^{24*}, Marco Schupp, MD^{24*}, Christina To, MD^{24*}, Paul Cheng, MD, PhD²⁴, Leo I. Gordon, MD²⁵ and Jason R. Westin, MD²⁶

[MI-Immune/1801: Lessons from an Ongoing, Multi-Center Trial Involving Biospecimen Collection for Prospective Microbiome and Immune Profiling in Patients Undergoing Reduced Intensity Conditioning Allogeneic HCT](#); **Erin Brooks, MS**^{1*}, Ashley Spahn^{2*}, Stephanie Waldvogel^{2*}, Alan Howard, PhD^{3*}, Merav Bar, MD⁴, Brandi Bratrude, PMP, CCRP^{5*}, Saurabh Chhabra, MD, MS⁶, William Clark, MD, MS^{7*}, Suman Ranjan Das, PhD^{8*}, Mary M. Horowitz, MD, MS⁹, Robert R. Jenq, MD¹⁰, Richard J. Jones, MD¹¹, John E. Levine, MD, MS¹², Brent R. Logan, PhD^{13*}, Hemant S. Murthy, MD¹⁴, Armin Rashidi, MD, PhD¹⁵, Marcie L. Riches, MD¹⁶, Mary Mansour Riwes, DO¹⁷, Karamjeet S. Sandhu, MD¹⁸, Anthony D. Sung, MD¹⁹, Monzr M. Al Malki, MD¹⁸, Lyndsey Runaas, MD^{20*}, Hany Elmariah, MD, MS²¹, Andrew R. Rezvani, MD²², Mahasweta Goptu, MD²³, Javier Bolaños-Meade, MD¹¹, Shernan G Holtan, MD²⁴, Wael Saber, MD, MS²⁵, Mehdi Hamadani, MD²⁶, Leslie S Kean, MD, PhD²⁷, Miguel-Angel Perales, MD²⁸ and Ami S. Bhatt, MD, PhD²⁹

[Long-Term Outcomes of Patients with Large B-Cell Lymphoma Treated with Standard-of-Care Axicabtagene Ciloleuce: Results from the US Lymphoma CAR-T Cell Consortium](#); **Jay Y. Spiegel, MD, FRCPC**¹, Michael D. Jain, MD, PhD², Loretta Nastoupil, MD³, John Tamaresis, PhD^{4*}, Armin Ghobadi, MD⁵, Yi Lin, MD, PhD⁶, Lazaros J. Lekakis, MD^{7*}, Patrick M. Reagan, MD⁸, Olalekan O. Oluwole, MBBS, MPH⁹, Joseph P. McGuirk, DO¹⁰, Abhinav Deol¹¹, Alison R. Sehgal, MD¹², Andre H. Goy, MD^{13*}, Brian T. Hill, MD¹⁴, Charalambos Andreadis, MD, MS¹⁵, Javier Muñoz, MD, MS, MBA, FACP¹⁶, Matthew L. Ulrickson, MD¹⁷, Jason R. Westin, MD¹⁸, Julio C. Chavez, MD, MS^{19*}, Miriam T. Jacobs, MD²⁰, N Nora Bennani, MD²¹, Aaron P. Rapoport, MD²², Julie M. Vose, MD, MBA²³, David B. Miklos, MD, PhD²⁴, Sattva S. Neelapu, MD³, Frederick L. Locke, MD²⁵, Saurabh Dahiya, MD²² and Matthew A. Lunning, DO, FACP²³

[Measurable Residual Disease Status and FLT3 Inhibitor Therapy in Patients with FLT3-ITD Mutated AML Following Allogeneic Hematopoietic Cell Transplantation;](#) **Emily C. Liang, MD¹**, Connie Chen^{2*}, Rong Lu, PhD^{3*}, Gabriel N. Mannis, MD⁴ and Lori Muffly, MD²

[First Salvage Therapy for Relapsed or Refractory Acute Myeloid Leukemia: Associated Health Care Resource Use and Costs;](#) **Lori Muffly, MD¹**, Christopher Young, PhD^{2*}, David Nimke, MPH, PhD^{2*}, Loretta Sullivan, MD, MPH^{2*}, Qi Feng, PhD, MS^{2*} and Bhavik J. Pandya, PharmD^{2*}

[The Intestinal Microbiota Correlates with Response and Toxicity after CAR T Cell Therapy in Patients with B-Cell Malignancies;](#) **Melody Smith, MD, MS¹**, Anqi Dai, MS^{2*}, Guido Ghilardi^{3*}, Kimberly Amelsberg^{3*}, Sean M Devlin, PhD^{4*}, Raymone Pajarillo, MS^{3*}, John B Slingerland^{5,6*}, Silvia Beghi^{7*}, Pamela S Herrera^{8*}, Paul A Giardina^{6*}, Annelie Clurman, BA^{6*}, Emmanuel A Dwomoh^{8*}, Gabriel K Armijo^{8*}, Antonio L.C. Gomes, PhD^{9*}, Eric R Littmann, BA^{10*}, Jonas Schluter^{11*}, Emily Fontana, BA^{12*}, Ying Taur, MD, MPH^{13*}, Jae H Park, MD¹⁴, Maria Lia Palomba¹⁵, Elizabeth Halton^{16*}, Josel D Ruiz, MPH^{17*}, Tania Jain, MD¹⁸, Martina Pennisi, MD^{19*}, Aishat Olaide Afuye, BA^{20*}, Miguel-Angel Perales, MD²¹, Craig W. Freyer, PharmD^{22*}, Alfred L Garfall, MD²³, Shannon H Gier, BS^{3*}, Sunita Nasta, MD^{24,25}, Daniel J Landsburg, MD²⁴, James N Gerson, MD²⁴, Jakub Svoboda, MD²⁴, Justin Cross, PhD^{26*}, Elise A Chong, MD²⁴, Sergio A Giralt, MD²⁷, Saar Gill, MD, PhD²⁸, Isabelle Rivière, PhD^{29*}, David L Porter, MD³⁰, Stephen J Schuster, MD³¹, Michel Sadelain, MD, PhD³², Noelle V Frey, MD, MS³³, Renier J Brentjens, MD, PhD¹⁴, Carl H June, MD^{3,34}, Eric G Pamer, MD^{10*}, Jonathan U Peled, MD³⁵, Marco Ruella, MD³⁶, Marcel van den Brink, MD, PhD¹⁷ and Andrea Facciabene, PhD^{37*}

[CD22-CAR T-Cell Therapy Mediates High Durable Remission Rates in Adults with Large B-Cell Lymphoma Who Have Relapsed after CD19-CAR T-Cell Therapy;](#) **Matthew J. Frank, MD, PhD^{1,2*}**, John H. Baird, MD^{1,2}, Shabnum Patel, PhD^{3*}, Juliana Craig, BA^{1,2*}, Jay Y. Spiegel, MD, FRCPC^{1,2}, Zachary Ehlinger, MS^{3*}, Harshini Chinnasamy, MS^{2*}, Sheren F. Younes, MD, PhD^{4*}, Jean S. Oak, MD, PhD^{5*}, Yasodha Natkunam, MD, PhD⁴, Warren D. Reynolds, BS^{3*}, Maria Iglesias, BS^{1,2*}, Emma Crawford, BS^{2,6*}, Hrishikesh K. Srinagesh, MD¹, Emily L. Egeler, PhD^{2*}, Sally Arai, MD, MS¹, Laura J. Johnston, MD¹, Robert Lowsky, MD¹, Robert S. Negrin, MD¹, Andrew R. Rezvani, MD¹, Parveen Shiraz, MD⁷, Surbhi Sidana, MD^{1,2}, Wen-Kai Weng, MD, PhD¹, Liora M. Schultz, MD⁸, Sneha Ramakrishna, MD⁸, Kara L. Davis, DO⁹, Bitu Sahaf, PhD^{2*}, Steven A. Feldman, PhD^{2*}, Crystal L. Mackall, MD^{2,10}, David B. Miklos, MD, PhD^{1,2} and Lori Muffly, MD^{1,2}

[Enrollment Characteristics and Outcomes of Hispanic and Black AYA ALL Patients Enrolled on a U.S. Intergroup Clinical Trial: A Comparison of the CALGB 10403 \(Alliance\) Cohort with U.S. Population-Level Data;](#) **Lori Muffly, MD¹**, Jun Yin, PhD², Sawyer Jacobson^{2*}, Anjali Advani, MD³, Selina M. Luger, MD, FRCPC⁴, Martin S. Tallman, MD⁵, Mark R. Litzow, MD⁶, Matthew C. Foster, MD⁷, Frederick R. Appelbaum, MD⁸, Richard A. Larson, MD⁹, Theresa Keegan, Ph.D.¹⁰ and Wendy Stock^{11*}

[Orca-T results in high GVHD-Free and Relapse-Free Survival following myeloablative conditioning for hematological malignancies: results of a single center phase 2 and a multicenter](#)

[phase 1b study](#); **Rasmus T. Hoeg, MD^{1*}**, Anna Moroz, MD, PhD^{2*}, Arpita Gandhi, MD³, Lori Muffly, MD⁴, Parveen Shiraz, MD⁵, Caspian Oliyai, MD⁶, Rohtesh S. Mehta, MD, MPH, MS⁷, Samer A Srour⁸, Joseph P. McGuirk, DO⁹, Edmund K. Waller, PhD, MD¹⁰, Sally Arai, MD, MS⁴, Laura J. Johnston, MD⁴, Robert Lowsky, MD⁴, Andrew R. Rezvani, MD⁴, Wen-Kai Weng, MD, PhD¹¹, David B. Miklos, MD, PhD⁴, Matthew J. Frank, MD, PhD^{12*}, John Tamaresis^{13*}, Ying Lu, PhD^{14*}, Vaibhav Agrawal^{13*}, Nathaniel B Fernhoff, PhD^{15*}, Gerhard Bauer^{16*}, Amy Putnam^{15*}, J Scott McClellan, MD, PhD¹⁷, Bronwen E. Shaw, MD, PhD¹⁸, Mehrdad Abedi, MD¹⁹, Robert S. Negrin, MD¹³ and Everett H Meyer, MD, PhD^{13*}

[Real-World Outcomes of Axicabtagene Ciloleucel \(Axi-cel\) for the Treatment of Large B-Cell Lymphoma \(LBCL\): Impact of Age and Specific Organ Dysfunction](#); **Frederick L. Locke, MD¹**, Caron Jacobson, MD², Long Ma, PhD^{3*}, Hua Dong, PhD^{3*}, Zhen-Huan Hu, PhD^{4*}, Tanya Siddiqi, MD⁵, Sairah Ahmed, MD^{6,7}, Armin Ghobadi, MD⁸, David B. Miklos, MD, PhD⁹, Yi Lin, MD, PhD¹⁰, Miguel-Angel Perales, MD¹¹, Matthew A. Lunning, DO, FACP¹², Megan M. Herr, PhD¹³, Brian T. Hill, MD¹⁴, Siddhartha Ganguly, MD^{15*}, Abu-Sayeed Mirza, MD, MPH¹⁶, Sarah Nikiforow, MD, PhD², Hairong Xu, MD, PhD^{3*} and Marcelo C Pasquini, MD, MS⁴

[Prediction of Early Onset Cytokine Release Syndrome and Neurologic Events After Axicabtagene Ciloleucel in Large B Cell Lymphoma Based on Machine Learning Algorithms](#); Qinghua Song, PhD^{1*}, Tao Hu, PhD^{1*}, **Sattva S. Neelapu, MD²**, Frederick L. Locke, MD³, Caron Jacobson, MD⁴, David B. Miklos, MD, PhD⁵, Olalekan O. Oluwole, MBBS, MPH⁶, Marie José Kersten, MD, PhD^{7,8}, Max Topp⁹, Jenny J. Kim, MD, MS^{1*}, Kanwarjit Singh, MD^{1*}, Jorge Andrade, PhD^{1*}, Lei Huang, PhD^{1*}, Allen Xue, PhD^{1*}, Marco Schupp, MD^{1*}, Myrna Nahas, MD^{1*}, Rhine R. Shen, PhD^{1*} and Adrian Bot, MD, PhD^{1*}

[Longterm \(≥4 Year and ≥5 Year\) Overall Survival \(OS\) by 12- and 24-Month Event-Free Survival \(EFS\): An Updated Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel \(Axi-Cel\) in Patients \(Pts\) with Refractory Large B-Cell Lymphoma \(LBCL\)](#); **Caron Jacobson, MD¹**, Frederick L. Locke, MD², Armin Ghobadi, MD³, David B. Miklos, MD, PhD⁴, Lazaros J. Lekakis^{5*}, Olalekan O. Oluwole, MBBS, MPH⁶, Yi Lin, MD, PhD⁷, Brian T. Hill, MD⁸, John M. Timmerman, MD⁹, Abhinav Deol¹⁰, Patrick M. Reagan, MD¹¹, Patrick Stiff, MD¹², Ian W. Flinn, MD, PhD¹³, Umar Farooq, MD¹⁴, Andre H. Goy, MD^{15*}, Javier Muñoz, MD, MS, MBA, FACP^{16*}, Tanya Siddiqi, MD¹⁷, Rhine R. Shen, PhD^{18*}, Adrian Bot, MD, PhD^{18*}, Jinghui Dong, PhD^{18*}, Kanwarjit Singh, MD^{18*}, Clare Spooner, MBBS^{18*}, Roshan Karalliyadda, PhD^{18*}, Jenny J. Kim, MD, MS^{18*}, Yan Zheng, MS^{18*} and Sattva S. Neelapu, MD¹⁹

[MGTA-145 + Plerixafor Provides G-CSF-Free Rapid and Reliable Hematopoietic Stem Cell Mobilization for Autologous Stem Cell Transplant in Patients with Multiple Myeloma: A Phase 2 study](#); **Surbhi Sidana, MD¹**, Andriyana K Bankova, MD^{1*}, Hitomi Hosoya, MD, PhD¹, Shaji K Kumar, MD², John Tamaresis, PhD^{3*}, Anne Le^{4*}, Lori Muffly, MD¹, Laura J. Johnston, MD¹, Sally Arai, MD, MS¹, Robert Lowsky, MD¹, Everett H Meyer, MD, PhD^{1*}, Andrew R. Rezvani, MD¹, Wen-Kai Weng, MD, PhD¹, Matthew J. Frank, MD, PhD¹, Parveen Shiraz, MD¹, Douglas Girenti, MD^{5*}, Kevin A. Goncalves, PhD^{5*}, Veit Schmelmer, PhD^{5*}, John C. Davis Jr., MD, MPH, MS^{5*}, Ying Lu, PhD^{3*}, Judith A Shizuru, MD, PhD¹ and David B. Miklos, MD, PhD¹

[Updated results from MajesTEC-1 – Phase ½ Study of Teclistamab a B-Cell Maturation Antigen X CD3 Antibody, in Relapsed/Refractory Multiple Myeloma](#); **Philippe Moreau, MD^{1*}**, Saad Z.

Usmani, MD MBA FACP², Alfred L. Garfall^{3*}, Niels W.C.J. van de Donk⁴, Hareth Nahi^{5*}, Jesus San-Miguel⁶, Albert Oriol^{7*}, Ajay K. Nooka⁸, Thomas Martin, MD⁹, Laura Rosinol^{10*}, Ajai Chari, MD^{11*}, Lionel Karlin^{12*}, Lotfi Benboubker^{13*}, Maria-Victoria Mateos¹⁴, Nizar J. Bahlis, MD¹⁵, Rakesh Popat, MBBS, FRCPath, PhD^{16*}, Britta Besemer^{17*}, Joaquín Martínez-López^{18*}, Surbhi Sidana, MD¹⁹, Lixia Pei^{20*}, Danielle Trancucci^{20*}, Raluca I. Verona^{21*}, Suzette Girgis²¹, Yunsi Olyslager^{22*}, Mindy Jaffe^{21*}, Clarissa M. Uhlar^{21*}, Tara Stephenson^{21*}, Rian Van Rampelbergh^{22*}, Arnob Banerjee^{21*}, Jenna D. Goldberg^{20*}, Rachel Kobos²⁰ and Amrita Y. Krishnan, MD²³

[Universal Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA Allo-715 Therapy for Relapsed/Refractory Multiple Myeloma; Sham Mailankody, MBBS¹, Michaela Liedtke, MD², Surbhi Sidana, MD³, Jeffrey V. Matous, MD⁴, Saurabh Chhabra, MD, MS⁵, Olalekan O. Oluwole, MBBS, MPH⁶, Shahbaz A. Malik, MD⁷, Shaji K Kumar, MD⁸, Rajneesh Nath, MD⁹, Faiz Anwer, MD¹⁰, Jose Carlos Cruz, MD¹¹, Sundar Jagannath, MD¹², Myo Htut¹³, Noopur S. Raje, MD¹⁴, David S. Siegel, MD, PhD¹⁵, Erin E. Karski, MD^{16*}, Wade Lovelace^{16*}, Afrodite Lourbakos, PhD^{16*}, Srinand Ponnathapura Nandakumar, PhD^{16*}, Arun Balakumaran, MD, PhD¹⁶ and Parameswaran Hari⁵](#)

Pre and Post-Treatment CD27+ T Cells Track with Clinical Efficacy of Axi-cel in DLBCL Patients